Real-world studies with a focus on PROs

Individual therapy goals are playing an increasingly important role in the modern, guideline-oriented treatment of psoriasis. In this context, real-world studies with biologics often not only record the reduction in PASI and BSA over the course of treatment, but also
various patient-related outcome parameters (“patient reported outcomes”) are also collected. The fact that interleukin (IL)-23 inhibitors also perform well in this respect has been confirmed in recently published
Interim analyses again.